GSK vs HYFT

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 04, 2026

GSK

53.4
AI Score
VS
GSK Wins

HYFT

43.3
AI Score

Investment Advisor Scores

GSK

53score
Recommendation
BUY

HYFT

43score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric GSK HYFT Winner
Forward P/E 19.084 0 Tie
PEG Ratio 95.4001 0 Tie
Revenue Growth 5.3% 49.8% HYFT
Earnings Growth -69.5% 0.0% HYFT
Tradestie Score 53.4/100 43.3/100 GSK
Profit Margin 14.5% -89.7% GSK
Beta 1.00 1.00 Tie
AI Recommendation BUY HOLD GSK

Relative Price Performance (Last 90 Days)

GSK 1M: -4.4% · 3M: -3.2% HYFT 1M: +3.1% · 3M: -21.4%

Current Technical Phase

GSK

Markdown
Sell / avoid

Price below a falling SMA50 (slope -0.2%), weak momentum, RSI 43

RSI (14): 42.7 · Price: $49.89

HYFT

Markdown
Sell / avoid

Price below a falling SMA50 (slope -7.1%), weak momentum, RSI 45

RSI (14): 44.8 · Price: $1.32

Fundamentals Snapshot

Metric GSK HYFT
Market Cap
Forward P/E 10.0 -7.1
Trailing P/E 16.0
Revenue (TTM)
Revenue Growth 0.1% 0.5%
Gross Margin 0.7% 0.6%
Operating Margin 0.3% -1.1%
EPS 3.18 -0.24
Dividend Yield 0.04%

Frequently Asked Questions

Based on our detailed analysis, GSK is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.